TY  - GEN
AU  - Nakatani,Fumihiko
AU  - Ferracin,Manuela
AU  - Manara,Maria Cristina
AU  - Ventura,Selena
AU  - Del Monaco,Valentina
AU  - Ferrari,Stefano
AU  - Alberghini,Marco
AU  - Grilli,Andrea
AU  - Knuutila,Sakari
AU  - Schaefer,Karl-Ludwig
AU  - Mattia,Gianfranco
AU  - Negrini,Massimo
AU  - Picci,Piero
AU  - Serra,Massimo
AU  - Scotlandi,Katia
TI  - miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy
SN  - 1096-9896
PY  - 2012///0427
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Biomarkers, Tumor
KW  - metabolism
KW  - Bone Neoplasms
KW  - drug therapy
KW  - Cell Line, Tumor
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Doxorubicin
KW  - pharmacology
KW  - Drug Resistance, Neoplasm
KW  - genetics
KW  - Drug Synergism
KW  - Humans
KW  - Imidazoles
KW  - In Situ Hybridization
KW  - Inhibitory Concentration 50
KW  - Kaplan-Meier Estimate
KW  - MicroRNAs
KW  - Multivariate Analysis
KW  - Oligonucleotide Array Sequence Analysis
KW  - Paraffin Embedding
KW  - Piperazines
KW  - Proportional Hazards Models
KW  - Real-Time Polymerase Chain Reaction
KW  - Reproducibility of Results
KW  - Retrospective Studies
KW  - Risk Assessment
KW  - Risk Factors
KW  - Sarcoma, Ewing
KW  - Time Factors
KW  - Transfection
KW  - Treatment Outcome
KW  - Tumor Suppressor Protein p53
KW  - Vincristine
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/path.3007
ER  -